Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RENEO PHARMA LTD

Home Clinical Trial Sponsors and OrganizationsRENEO PHARMA LTD

RENEO PHARMA LTD

Second Floor Office 20, Sandwich, United Kingdom

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

24

15 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

19

79.2%

Phase 2

4

16.7%

Trial Status Distribution

Active, not recruiting

14

58.3%

Completed

6

25.0%

Not yet recruiting

1

4.2%

Recruiting

1

4.2%

Terminated

2

8.3%

Clinical Trials

Trials sponsored by this organization (24)

An unblinded , multi-centre study to determine the long term safety and tolerability of the study drug REN001 in Primary Mitochondrial Myopathy (PMM) subjects.

Jul 2022200 participants

Mass balance study of [14C]-REN001 in healthy male subjects

Jul 20226 participants

To study the effectiveness and safety of REN001 in PMM patients after 24 weeks of treatment

Active, not recruiting

Apr 2022200 participants

To study the effectiveness and safety of REN001 in PMM patients after 24 weeks of treatment

Active, not recruiting

Mar 2022200 participants

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Feb 2022155 participants

An unblinded , multi-centre study to determine the long term safety and tolerability of the study drug REN001 in Primary Mitochondrial Myopathy (PMM) subjects.

Active, not recruiting

Dec 202180 participants

An unblinded , multi-centre study to determine the long term safety and tolerability of the study drug REN001 in Primary Mitochondrial Myopathy (PMM) subjects.

Active, not recruiting

Dec 2021200 participants

An unblinded , multi-centre study to determine the long term safety and tolerability of the study drug REN001 in Primary Mitochondrial Myopathy (PMM) subjects.

Active, not recruiting

Dec 2021200 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials24
Approvals
News

Back to Organizations